EGFR and non-small cell lung carcinoma: In our recent study, we demonstrated that PhosphoFlowSeq reproduciblyenriches the resistance mutation T790M in several independent selectionexperiments performed in the presence of the EGFR-directed kinaseinhibitor erlotinib.19 Since T790M is alsoby far the most frequently observed mutation in the EGFR gene upon erlotinib treatment of NSCLC patients,20 those experiments validated PhosphoFlowSeq as a reproduciblemethod, enabling the identification of clinically relevant EGFR mutations.